세계의 보툴리눔톡신(보톡스) 시장 : 제품별, 유형별, 연령층별, 용도별, 최종사용자별, 지역별 - 예측(-2030년)

The global botulinum toxins market is projected to reach USD 15.7 billion by 2030 from USD 8.9 billion in 2025, at a CAGR of 11.7% during the forecast period.

The growth of the market can be attributed to the increasing societal and occupational emphasis on looking youthful, especially in urban and professional environments. This trend encourages more individuals to seek cosmetic procedures, including the use of botulinum toxins. In developing countries, rising disposable incomes and exposure to urban lifestyles are creating new patient demographics, which significantly increases the demand for botulinum toxins. These factors are expected to drive the market for botulinum toxins during the forecast period.

"Based on product, Botox held the largest share of the botulinum toxins market in 2024."

The botulinum toxins market is divided by product into major brands, including Botox, Dysport, Jeuveau, Myobloc, Xeomin, and other products. In 2024, Botox held the largest share of the market. The brand has established a strong reputation for clinical reliability, which instills confidence among cosmetologists, dermatologists, and aestheticians, as well as trust from end users such as clinics, spas, and hospitals. Botox offers a wide range of applications and demonstrates a safe and effective profile compared to its competitors.

Botox is utilized in various medical fields, including neurology, dermatology, urology, ophthalmology, and rehabilitation medicine, contributing to its increasing demand. Additionally, Botox provides extensive training modules and patient support programs. These factors have enabled Botox to surpass its competitors and secure a leading position in the botulinum toxins market.

"Based on type, the type A botulinum toxins segment held the largest share of the market in 2024."

The botulinum toxins market is divided into two main categories based on type: type A and type B botulinum toxins. Type A botulinum toxins occupy a significant share of the global market, primarily due to their proven clinical effectiveness and long history of regulatory approvals. Being the first serotype in this category, type A is supported by substantial evidence demonstrating its safety and efficacy in both therapeutic and aesthetic applications.

Type A is authorized for a wide range of uses around the world, including treatments for chronic migraines, spasticity, and reducing facial wrinkles, which contributes to its widespread adoption. Additionally, type A offers a longer-lasting effect, typically lasting between three and six months, resulting in fewer treatment sessions and greater patient convenience.

These factors reinforce type A's dominant position in manufacturing, sales, and demand within the botulinum toxins industry. In comparison, type A is preferred over type B because it provides effects lasting longer (up to six months) and has more extensive regulatory approvals for aesthetic and therapeutic purposes. It is also more potent at smaller doses and less likely to develop antibody resistance. Furthermore, type A is widely recognized among physicians, supported by extensive clinical experience and research, which cements its leading market position globally.

"Based on applications, the aesthetics segment commanded the largest market share in 2024."

The aesthetics segment, particularly wrinkle removal, is expected to dominate the botulinum toxins market. In 2024, wrinkle removal continues to be a popular and well-recognized application of botulinum toxins, especially among adults seeking non-surgical anti-aging solutions. Clinics report high patient volumes, primarily for the treatment of forehead lines, crow's feet, and glabellar (frown) lines. This popularity is attributed to the visible and relatively quick results, along with fewer treatment cycles needed, making it widely accepted across diverse demographics. The procedure duration is short, and the results are noticeable quickly, leading to its prominence among non-surgical options.

"Based on end users, the dermatology clinics & hospitals segment accounted for the largest share in 2024."

The global botulinum toxins market is segmented by end user into dermatology clinics & hospitals, beauty centers, medical spas, and other end users. In 2024, dermatology clinics & hospitals witnessed a significant demand for botulinum toxin products, as they serve as primary providers for both aesthetic and medical procedures.

Dermatology clinics primarily focus on cosmetic treatments, such as wrinkle reduction and facial contouring, which are among the most common applications of botulinum toxins. In contrast, hospitals use these toxins to treat various medical conditions, including muscle spasticity, chronic migraines, and dystonia. With their well-equipped facilities, access to trained professionals, and capacity to manage both routine and complex cases, hospitals and clinics are key players that drive consistent usage of botulinum toxin products.

"The market in North America is expected to hold a significant market share for botulinum toxins throughout the forecast period."

The botulinum toxins market comprises five key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, the North America region held a significant market share for botulinum toxins. This growth is primarily attributed to a strong healthcare infrastructure and the considerable disposable income of the population. North America is also home to several major manufacturers of botulinum toxins, fostering a sustainable ecosystem of buyers, distributors, and suppliers. These factors are anticipated to contribute to the growth of the botulinum toxins market in North America.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1 (35%), Tier 2 (45%), and Tier 3 (20%)
• By Designation: C-level Executives (35%), Directors (25%), and Others (40%)
• By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%), and the Middle East & Africa (5%)

The key players profiled in the botulinum toxins market are by AbbVie Inc. (US), Ipsen Biopharmaceuticals Inc. (France), Galderma (Switzerland), Hugel, Inc. (South Korea), Revance Therapeutics, Inc. (US), Evolus, Inc. (US), Medytox, Inc. (South Korea), Merz Pharmaceuticals GmbH (Germany), Supernus Pharmaceuticals, Inc. (US), Daewoong Pharmaceutical Co., Ltd. (South Korea), Huons Co., Ltd. (South Korea), Eisai Co., Ltd. (Japan) and Hugh Source (International) Ltd. (Hong Kong).

Research Coverage

The research report examines the botulinum toxins market by product, type, application, end user, and region. This research examines the factors contributing to market expansion, analyzes the challenges and opportunities currently faced by various industries, and provides details on the competitive landscape, including both market leaders and small to medium-sized enterprises. Additionally, it estimates the revenue generated by different market segments across five regions and includes a micromarket analysis.

Reasons to Buy the Report

The report will assist market leaders and new entrants by providing accurate revenue estimates for the overall botulinum toxins market and its subsegments. It will help stakeholders understand the competitive landscape, allowing them to position their businesses more effectively and develop appropriate go-to-market strategies. Additionally, the report offers insights into the market dynamics, including key drivers, restraints, challenges, and opportunities.

This report provides insightful data on the following points:

• Market Penetration: In-depth coverage of product portfolios offered by the top players in the botulinum toxins market.
• Product Development/Innovation: In-depth coverage of product portfolios offered by the top players in the botulinum toxins market.
• Market Development: Insightful data on profitable developing areas.
• Market Diversification: Details about recent developments and advancements in the botulinum toxins market.
• Competitive Assessment: Extensive assessment of the products, growth tactics, revenue projections, and market categories of the top competitors.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY RESEARCH
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Key data from secondary sources
    • 2.1.1.3 Objectives of secondary research
  • 2.1.2 PRIMARY RESEARCH
    • 2.1.2.1 Key primary sources
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Company revenue estimation
    • 2.2.1.2 Customer-based market estimation
    • 2.2.1.3 Primary interviews
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 GROWTH RATE ASSUMPTIONS
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 BOTULINUM TOXINS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: BOTULINUM TOXINS MARKET, BY APPLICATION AND COUNTRY, 2024 (USD MILLION)
• 4.3 BOTULINUM TOXINS MARKET: EMERGING VS. DEVELOPED MARKETS, 2025 VS. 2030 (USD MILLION)
• 4.4 BOTULINUM TOXINS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increased adoption in therapeutic indications
    • 5.2.1.2 Reduced out-of-pocket expenditure due to sufficient reimbursement schemes
    • 5.2.1.3 Aesthetic consciousness among adults
    • 5.2.1.4 Greater acceptance and normalization of botulinum toxins among millennials and Gen Z
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Risk of infection and safety concerns
    • 5.2.2.2 Complex regulatory framework and compliance standards
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 High growth opportunities in emerging economies
    • 5.2.3.2 Formulation advancements and innovations for improved safety
  • 5.2.4 CHALLENGES
    • 5.2.4.1 High treatment costs
    • 5.2.4.2 Social and cultural barriers
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF BOTULINUM TOXINS, BY KEY PLAYER, 2022-2024
  • 5.4.2 AVERAGE SELLING PRICE TREND OF BOTULINUM TOXINS, BY REGION, 2022-2024
• 5.5 VALUE CHAIN ANALYSIS
  • 5.5.1 RESEARCH & DEVELOPMENT
  • 5.5.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING
  • 5.5.3 DISTRIBUTION AND MARKETING & SALES
  • 5.5.4 AFTER-SALES SERVICES
• 5.6 SUPPLY CHAIN ANALYSIS
  • 5.6.1 PROMINENT COMPANIES
  • 5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
  • 5.6.3 END USERS
• 5.7 ECOSYSTEM ANALYSIS
  • 5.7.1 ROLE IN ECOSYSTEM
• 5.8 INVESTMENT & FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Jet-based delivery systems
    • 5.9.1.2 Facial imaging and mapping systems
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Laser, RF, & ultrasound-based devices
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 3D imaging and AI-based facial mapping
• 5.10 PATENT ANALYSIS
  • 5.10.1 INNOVATIONS AND PATENT REGISTRATIONS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT DATA FOR HS CODE 300290, 2020-2024
  • 5.11.2 EXPORT DATA FOR HS CODE 300290, 2020-2024
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 CASE STUDY ANALYSIS
  • 5.13.1 COMMERCIAL PARTNERSHIPS BY ANIKA THERAPEUTICS TO INCREASE MEDICAL AESTHETIC PRODUCT SALES
  • 5.13.2 DIVISION OF BUSINESS BY MERZ BIOPHARMA TO HELP EFFECIENTLY MEET CUSTOMER DEMANDS
  • 5.13.3 COLLABORATIONS BETWEEN CANDELA CORPORATION AND SMES TO STREAMLINE LASER-BASED DEVICES
• 5.14 REGULATORY ANANLYSIS
  • 5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.14.2 KEY REGULATORY GUIDELINES
    • 5.14.2.1 North America
      • 5.14.2.1.1 US
      • 5.14.2.1.2 Canada
    • 5.14.2.2 Europe
      • 5.14.2.2.1 UK
      • 5.14.2.2.2 France
      • 5.14.2.2.3 Germany
    • 5.14.2.3 Asia Pacific
      • 5.14.2.3.1 China
      • 5.14.2.3.2 Japan
      • 5.14.2.3.3 India
    • 5.14.2.4 Latin America
      • 5.14.2.4.1 Brazil
    • 5.14.2.5 Middle East & Africa
      • 5.14.2.5.1 UAE
  • 5.14.3 REGULATORY STANDARDS/APPROVALS
• 5.15 REIMBURSEMENT SCENARIO ANALYSIS
  • 5.15.1 NORTH AMERICA
    • 5.15.1.1 US
    • 5.15.1.2 Canada
  • 5.15.2 EUROPE
    • 5.15.2.1 UK
    • 5.15.2.2 Germany
    • 5.15.2.3 France
    • 5.15.2.4 Italy
    • 5.15.2.5 Spain
  • 5.15.3 ASIA PACIFIC
    • 5.15.3.1 China
    • 5.15.3.2 Japan
    • 5.15.3.3 India
    • 5.15.3.4 Australia
  • 5.15.4 LATIN AMERICA
    • 5.15.4.1 Brazil
    • 5.15.4.2 Mexico
  • 5.15.5 MIDDLE EAST & AFRICA
    • 5.15.5.1 GCC Countries
    • 5.15.5.2 Africa (Major Economies)
• 5.16 PORTER'S FIVE FORCE ANALYSIS
  • 5.16.1 THREAT OF NEW ENTRANTS
  • 5.16.2 THREAT OF SUBSTITUTES
  • 5.16.3 BARGAINING POWER OF SUPPLIERS
  • 5.16.4 BARGAINING POWER OF BUYERS
  • 5.16.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.17 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.17.2 BUYING CRITERIA
• 5.18 UNMET NEEDS
• 5.19 IMPACT OF 2025 US TARIFF ON BOTULINUM TOXINS MARKET
  • 5.19.1 INTRODUCTION
  • 5.19.2 KEY TARIFF RATES
  • 5.19.3 PRICE IMPACT ANALYSIS
  • 5.19.4 IMPACT ON COUNTRY/REGION
    • 5.19.4.1 North America
      • 5.19.4.1.1 US
    • 5.19.4.2 Europe
    • 5.19.4.3 Asia Pacific
  • 5.19.5 IMPACT ON END-USE INDUSTRIES
• 5.20 IMPACT OF AI/GEN AI ON BOTULINUM TOXINS MARKET
  • 5.20.1 MARKET POTENTIAL OF AI/GEN AI
  • 5.20.2 AI USE CASES
  • 5.20.3 KEY COMPANIES IMPLEMENTING AI/GEN AI
  • 5.20.4 FUTURE OF AI/GEN AI

6 BOTULINUM TOXINS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 BOTOX
  • 6.2.1 USE IN THERAPEUTIC AND COSMETIC PROCEDURES TO AUGMENT MARKET GROWTH
• 6.3 DYSPORT
  • 6.3.1 FASTER ONSET DURATION AND LONG-LASTING EFFECT TO BOOST MARKET ADOPTION
• 6.4 JEUVEAU
  • 6.4.1 INTRODUCTION OF TECH-ENABLED PLATFORMS FOR CONSUMER SUPPORT TO FUEL MARKET GROWTH
• 6.5 MYOBLOC
  • 6.5.1 WIDE THERAPEUTIC PROFILE TO DRIVE MARKET
• 6.6 XEOMIN
  • 6.6.1 STABLE THERAPEUTIC PERFORMANCE AND EFFECTIVE FORMULATION TO FAVOR MARKET GROWTH
• 6.7 OTHER PRODUCTS

7 BOTULINUM TOXINS MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 TYPE A BOTULINUM TOXINS
  • 7.2.1 GLOBAL CLINICAL ACCEPTANCE AND PROVEN EFFICACY TO SUPPORT MARKET GROWTH
• 7.3 TYPE B BOTULINUM TOXINS
  • 7.3.1 WIDE THERAPEUTIC UTILITY AND DISTINCT CLINICAL PROFILE TO PROPEL MARKET GROWTH

8 BOTULINUM TOXINS MARKET, BY AGE GROUP

• 8.1 INTRODUCTION
• 8.2 17 YEARS OR YOUNGER
  • 8.2.1 INCREASING THERAPEUTIC USE OF BOTOX TO PROPEL MARKET GROWTH AMONG YOUNGER PEOPLE
• 8.3 18-34 YEARS
  • 8.3.1 GOOD TOLERABILITY AND IMPROVED PATIENT-REPORTED OUTCOMES TO DRIVE ADOPTION OF BOTOX TREATMENT
• 8.4 35-50 YEARS
  • 8.4.1 NEED FOR APPEARANCE MAINTENANCE AND BETTER SOCIAL ENGAGEMENT TO FUEL MARKET GROWTH
• 8.5 51-64 YEARS OLD
  • 8.5.1 SUSTAINED DEMAND FOR COSMETIC AND THERAPEUTIC INDICATIONS TO AUGMENT MARKET GROWTH
• 8.6 65 YEARS OR OLDER
  • 8.6.1 HIGH DEMAND FOR FUNCTIONAL IMPROVEMENTS AND CONSERVATIVE AESTHETIC ENHANCEMENTS TO DRIVE MARKET

9 BOTULINUM TOXINS MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 COSMETIC APPLICATIONS
  • 9.2.1 WRINKLE REMOVAL
    • 9.2.1.1 Surge in beauty clinics and medical spas to support segment growth
  • 9.2.2 FACIAL CONTOURING
    • 9.2.2.1 Rising desire for natural results and growing appeal of minimally invasive procedures to propel segment growth
  • 9.2.3 SKIN REJUVENATION
    • 9.2.3.1 Increased adoption of minimally invasive facial enhancement procedures to boost market growth
• 9.3 THERAPEUTIC APPLICATIONS
  • 9.3.1 PAIN MANAGEMENT
    • 9.3.1.1 Rising need for pain management techniques to drive segment
  • 9.3.2 OVERACTIVE BLADDER
    • 9.3.2.1 Localized mechanism, strong efficacy, and long-lasting relief to spur demand for botulinum toxins among neurogenic patients
• 9.4 OTHER APPLICATIONS

10 BOTULINUM TOXINS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 DERMATOLOGY CLINICS & HOSPITALS
  • 10.2.1 RISING TREND OF MEDICAL TOURISM AND INCREASING POPULARITY OF PLASTIC SURGERY TO SUPPORT MARKET GROWTH
• 10.3 BEAUTY CENTERS
  • 10.3.1 GROWING INCLINATION TOWARD CUSTOMIZED TREATMENTS TO BOOST MARKET GROWTH
• 10.4 MEDICAL SPAS
  • 10.4.1 INCREASING FOCUS ON CONVENIENCE, TREATMENT FLEXIBILITY, AND COST EFFECTIVENESS TO SPUR MARKET GROWTH
• 10.5 OTHER END USERS

11 BOTULINUM TOXINS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 US to dominate North American botulinum toxins market during study period
  • 11.2.3 CANADA
    • 11.2.3.1 Preference for minimally invasive cosmetic procedures among aging individuals to drive market growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Selective reimbursement regimes and large number of cosmetic procedures to spur market demand
  • 11.3.3 UK
    • 11.3.3.1 Increased demand for Botox for cosmetic enhancements to propel market growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Increased awareness and broader societal acceptance of cosmetic treatments to augment market growth
  • 11.3.5 ITALY
    • 11.3.5.1 Rising number of medical aesthetic procedures to aid market growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Growing availability of safe and effective minimally invasive or non-invasive aesthetic treatments to aid market growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 Popularity of medical tourism to increase demand for cosmetic treatments
  • 11.4.3 CHINA
    • 11.4.3.1 Surging demand for non-surgical aesthetic procedures to support market growth
  • 11.4.4 INDIA
    • 11.4.4.1 Lack of reimbursements for aesthetic treatments alongside social and ethical concerns to limit market growth
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Increased number of aesthetic procedures to grow market for botulinum toxins
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Rising availability of safe and effective minimally invasive and non-invasive aesthetic procedures and products to drive market
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Rapid growth in medical tourism and high disposable incomes to expedite market growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Rising influx of medical tourists from US to drive adoption of cost-effective cosmetic procedures
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Favorable government policies to propel market growth
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYERS' STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BOTULINUM TOXINS MARKET
• 12.3 REVENUE ANALYSIS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.4.1 MARKET RANKING OF KEY PLAYERS, 2024
• 12.5 COMPANY VALUATION & FINANCIAL METRICS
  • 12.5.1 FINANCIAL METRICS
  • 12.5.2 COMPANY VALUATION
• 12.6 BRAND/PRODUCT COMPARISON
• 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.7.1 STARS
  • 12.7.2 PERVASIVE PLAYERS
  • 12.7.3 EMERGING LEADERS
  • 12.7.4 PARTICIPANTS
  • 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.7.5.1 Company footprint
    • 12.7.5.2 Region footprint
    • 12.7.5.3 Type footprint
    • 12.7.5.4 Application footprint
    • 12.7.5.5 End-user footprint
• 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.8.1 PROGRESSIVE COMPANIES
  • 12.8.2 RESPONSIVE COMPANIES
  • 12.8.3 DYNAMIC COMPANIES
  • 12.8.4 STARTING BLOCKS
  • 12.8.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2024
    • 12.8.5.1 Detailed list of key startups/SMEs
    • 12.8.5.2 Competitive benchmarking of key startups/SMEs
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES & APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 ABBVIE INC.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Deals
      • 13.1.1.3.2 Expansions
      • 13.1.1.3.3 Other developments
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 IPSEN BIOPHARMACEUTICALS, INC.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product approvals
      • 13.1.2.3.2 Expansions
      • 13.1.2.3.3 Other developments
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 GALDERMA
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches
      • 13.1.3.3.2 Deals
      • 13.1.3.3.3 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 HUGEL, INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product approvals
      • 13.1.4.3.2 Deals
      • 13.1.4.3.3 Expansions
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 REVANCE
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product launches & approvals
      • 13.1.5.3.2 Deals
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 EVOLUS, INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product launches & approvals
      • 13.1.6.3.2 Deals
  • 13.1.7 MEDYTOX
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product approvals
      • 13.1.7.3.2 Deals
  • 13.1.8 MERZ PHARMA
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product approvals
  • 13.1.9 SUPERNUS PHARMACEUTICALS, INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
  • 13.1.10 DAEWOONG PHARMACEUTICAL CO., LTD.
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Product launches & approvals
  • 13.1.11 HUONS
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product launches & approvals
  • 13.1.12 EISAI CO., LTD.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
  • 13.1.13 HUGH SOURCE (INTERNATIONAL) LTD.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 DERMAX CO., LTD.
  • 13.2.2 GUFIC BIOSCIENCES
  • 13.2.3 OCEAN PHARMACEUTICAL
  • 13.2.4 CROMA-PHARMA GMBH
  • 13.2.5 MICROGEN
  • 13.2.6 JDBIO CO., LTD.
  • 13.2.7 CKD BIO
  • 13.2.8 ATRAZIST ARAY CO.
  • 13.2.9 GUANGZHOU AOMA BUSINESS CO., LTD.
  • 13.2.10 JETEMA CO., LTD.
  • 13.2.11 SINOPHARM GROUP CO., LTD.
  • 13.2.12 QUFU HANTANG BIOTECHNOLOGY CO., LTD.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS